Rules for Making Human Tumor Cells, New England Journal of Medicine, vol.347, issue.20, pp.1593-603, 2002. ,
DOI : 10.1056/NEJMra021902
Cancer genes and the pathways they control, Nature Medicine, vol.1, issue.8, pp.789-99, 2004. ,
DOI : 10.1038/sj.onc.1207130
DNA methylation and gene silencing in cancer, Nature Clinical Practice Oncology, vol.249, issue.1, pp.4-11, 2005. ,
DOI : 10.1038/ncponc0354
Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers, Yonsei Medical Journal, vol.50, issue.4, pp.455-63, 2009. ,
DOI : 10.3349/ymj.2009.50.4.455
DNA Methylation as a Therapeutic Target in Cancer, Clinical Cancer Research, vol.13, issue.6, pp.1634-1641, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2076
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia The potential role of epigenetic therapy in multiple myeloma Molecular pathogenesis and a consequent classification of multiple myeloma Advances in biology of multiple myeloma: clinical applications, Blood. Br J Haematol. J Clin Oncol. Blood, vol.11123104, issue.10, pp.2382-46333, 2004. ,
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma, Eur J Haematol. Int J Cancer, vol.82125, issue.12, pp.176-831985, 2009. ,
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma, Blood, vol.101, issue.7, pp.2784-2792, 2003. ,
DOI : 10.1182/blood-2002-06-1735
von Hippel???Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease, Clinical Lymphoma and Myeloma, vol.9, issue.3, pp.239-281, 2009. ,
DOI : 10.3816/CLM.2009.n.047
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation Frequent hypermethylation of p16 and p15 genes in multiple myeloma, Cancer Res. Blood, vol.6589, issue.16, pp.4673-822500, 1997. ,
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma, Experimental Hematology, vol.36, issue.12, pp.1673-81, 2008. ,
DOI : 10.1016/j.exphem.2008.08.001
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma, Genome Cancer Res. Epigenetics. Blood, vol.686, issue.21, pp.44-541047, 2008. ,
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011. ,
DOI : 10.3324/haematol.2010.033456
URL : https://hal.archives-ouvertes.fr/inserm-00550232
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, pp.4727-4764, 1998. ,
Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, pp.514-538, 1999. ,
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients, Leukemia. Ann Hematol, vol.1482, issue.27, pp.188-97654, 2000. ,
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, pp.194-203, 2005. ,
DOI : 10.1002/gcc.20231
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies, Blood, vol.107, issue.7, pp.2633-2641, 2006. ,
DOI : 10.1182/blood-2005-10-4084
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma, Blood. Blood, vol.113112, issue.31, pp.4614-264235, 2008. ,
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004. ,
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1051, 2005. ,
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406
A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, pp.16-36, 2008. ,
DOI : 10.1186/1471-2105-9-16
URL : https://hal.archives-ouvertes.fr/inserm-00268075
An Online Resource to Google and Visualize Public Human whole Genome Expression Data, The Open Bioinformatics Journal, vol.4, pp.5-10, 2010. ,
Statistical tests for differential expression in cDNA microarray experiments, Genome Biol, vol.4, 2003. ,
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006. ,
The molecular characterization and clinical management of multiple myeloma in the post-genome era Interferon-alpha induces reversible DNA demethylation of the interferon-induced transmembrane protein-3 core promoter in human melanoma cells IFNalpha is a survival factor for human myeloma cells and reduces dexamethasoneinduced apoptosis, Leukemia. J Interferon Cytokine Res. J Immunol, vol.2331161, issue.42, pp.1941-56, 1998. ,
Differential Myeloma Cell Responsiveness to Interferon-alpha Correlates with Differential Induction of p19INK4d and Cyclin D2 Expression, Journal of Biological Chemistry, vol.273, issue.19, pp.11799-805, 1998. ,
DOI : 10.1074/jbc.273.19.11799
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321, Journal of Clinical Oncology, vol.24, issue.6, pp.929-965, 2006. ,
DOI : 10.1200/JCO.2005.04.5807
A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results Clinical and biological significance of RAS mutations in multiple myeloma, Br J Haematol. Leukemia, vol.10222, issue.47, pp.495-5022280, 1998. ,
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival, Blood, vol.117, issue.6, pp.1998-2004, 2011. ,
DOI : 10.1182/blood-2010-05-284422
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors, Blood, vol.105, issue.1, pp.317-340, 2005. ,
DOI : 10.1182/blood-2004-03-0833
Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial, Blood, vol.88, pp.2699-706, 1996. ,
RecQ helicases: multifunctional genome caretakers, Nature Reviews Cancer, vol.32, issue.9, pp.644-54, 2009. ,
DOI : 10.1038/nrc2682
Human diseases deficient in RecQ helicases, Biochimie, vol.85, issue.11 ,
DOI : 10.1016/j.biochi.2003.10.006
RecQ helicases: caretakers of the genome, Nature Reviews Cancer, vol.28, issue.3, pp.169-78, 2003. ,
DOI : 10.1038/nrc1012
RECQL1 and WRN Proteins Are Potential Therapeutic Targets in Head and Neck Squamous Cell Carcinoma, Cancer Research, vol.71, issue.13, pp.4598-607, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-0320
The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation, Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models, pp.1227-3683, 2008. ,
DOI : 10.2174/1568011053765985
Analysis of the kinesin superfamily: insights into structure and function, Trends in Cell Biology, vol.15, issue.9, pp.467-76, 2005. ,
DOI : 10.1016/j.tcb.2005.07.006
Kinesin and Dynein Superfamily Proteins and the Mechanism of Organelle Transport, Science, vol.279, issue.5350, pp.519-545, 1998. ,
DOI : 10.1126/science.279.5350.519
The role of kinesin family proteins in tumorigenesis and progression, Cancer, vol.283, issue.pt 22, pp.5150-60, 2010. ,
DOI : 10.1002/cncr.25461
Functional Analysis of Human Microtubule-based Motor Proteins, the Kinesins and Dyneins, in Mitosis/Cytokinesis Using RNA Interference, Molecular Biology of the Cell, vol.16, issue.7, pp.3187-99, 2005. ,
DOI : 10.1091/mbc.E05-02-0167
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma, Journal of Clinical Oncology, vol.27, issue.27, pp.4585-90, 2009. ,
DOI : 10.1200/JCO.2008.20.6136
The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma, Clinical Cancer Research, vol.17, issue.23, pp.7402-7414, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0596